We are live on ! Find out more
FULC icon

Fulcrum Therapeutics

129 hedge funds and large institutions have $496M invested in Fulcrum Therapeutics in 2025 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 40 increasing their positions, 43 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,213% more call options, than puts

Call options by funds: $1.64M | Put options by funds: $125K

44% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 18

32% more capital invested

Capital invested by funds: $374M → $496M (+$121M)

6% more funds holding

Funds holding: 122129 (+7)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

7% less repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 43

1.34% less ownership

Funds ownership: 100.78%99.44% (-1.3%)

Holders
129
Holders Change
+7
Holders Change %
+5.74%
% of All Funds
1.69%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
26
Increased
40
Reduced
43
Closed
18
Calls
$1.64M
Puts
$125K
Net Calls
+$1.52M
Net Calls Change
-$4.11M
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$94.1M
SCM
2
Suvretta Capital Management
New York
$49.5M +$2.16M +298,100 +6%
TCM
3
TCG Crossover Management
California
$48.3M
NCM
4
Nantahala Capital Management
Connecticut
$43M +$2.77M +382,485 +9%
BlackRock
5
BlackRock
New York
$34.1M -$4.86M -672,273 -15%
Vanguard Group
6
Vanguard Group
Pennsylvania
$27.6M -$1.06M -146,979 -5%
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$22.4M -$15.6M -2,157,000 -47%
Balyasny Asset Management
8
Balyasny Asset Management
Illinois
$13.3M +$812K +112,266 +8%
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$13.3M +$1.97M +272,712 +23%
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$12M -$531K -73,329 -5%
IC
11
Ikarian Capital
Texas
$11.9M +$6.23M +860,704 +201%
State Street
12
State Street
Massachusetts
$9.78M -$1.12M -155,159 -13%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$9.24M -$1.37M -189,087 -16%
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$9.21M +$7.21M +996,632 +23,634%
Citadel Advisors
15
Citadel Advisors
Florida
$7.86M +$4.98M +688,322 +414%
BFM
16
Boothbay Fund Management
New York
$6.24M +$3.89M +537,036 +380%
Goldman Sachs
17
Goldman Sachs
New York
$5.39M -$4.03M -557,185 -49%
Northern Trust
18
Northern Trust
Illinois
$5.23M -$313K -43,214 -7%
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
$4.97M -$165K -22,739 -4%
Connor, Clark & Lunn Investment Management (CC&L)
20
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$3.53M +$301K +41,591 +12%
SSA
21
Schonfeld Strategic Advisors
New York
$3.37M +$1.17M +161,903 +79%
ACM
22
ADAR1 Capital Management
Texas
$3.14M +$2.09M +288,263 +540%
Charles Schwab
23
Charles Schwab
California
$3.07M -$393K -54,299 -14%
Jane Street
24
Jane Street
New York
$2.96M +$2.2M +304,093 +1,745%
UBS Group
25
UBS Group
Switzerland
$2.77M +$1.2M +165,952 +123%

FULC Hedge Fund Activity: Q3 2025 in Review

129 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q3 2025, worth a combined $496M — up 32% from $374M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new FULC positions and 18 closed out — a net gain of 8 holders — while 40 added to existing stakes and 43 trimmed.

The largest buyer was Royal Bank of Canada, adding an estimated $7.21M. The largest seller was Adage Capital Partners, cutting an estimated $15.6M.

  • 129 institutional investors held Fulcrum Therapeutics (FULC) as of Q3 2025, up from 122 in Q2 2025.
  • Funds reported $496M of Fulcrum Therapeutics stock for Q3 2025, up 32% quarter-over-quarter.
  • 26 funds opened new Fulcrum Therapeutics positions in Q3 2025 and 18 closed out, a net change of +8 holders.
  • The largest Fulcrum Therapeutics buyer in Q3 2025 was Royal Bank of Canada, an estimated $7.21M added.
  • The largest Fulcrum Therapeutics seller in Q3 2025 was Adage Capital Partners, an estimated $15.6M sold.

Based on aggregated 13F filings for Q3 2025.